Negative Impact of p21-Activated Kinase 4-Mediated AMP-Activated Protein Kinase Inhibition on Sarcopenia in Mice and Humans.

Jiacheng Du, Hwang Chan Yu, Young Jae Moon, Sun-Jung Yoon, Seung-Yong Seo, Byung-Hyun Park, Eun Ju Bae

Department of Biochemistry and Molecular Biology Jeonbuk National University Medical School Jeonju Republic of Korea.Department of Biochemistry and Molecular Biology Jeonbuk National University Medical School Jeonju Republic of Korea. · pubmed

Paper

Abstract

We recently identified that AMP-activated protein kinase (AMPK) α2 phosphorylation at S491 is mediated by p21-activated kinase 4 (PAK4), leading to muscular and systemic insulin resistance. This study examined how muscle PAK4 deletion affects atrophy in male mice and its link to human sarcopenia. Dexamethasone treatment increased the mRNA and protein levels of PAK4, which was partially the result of glucocorticoid response elements activation in the promoter of the

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that PAK4-mediated inhibition of AMPK contributes to muscle atrophy and insulin resistance, linking these mechanisms to sarcopenia in both mice and humans. This research addresses the underlying mechanisms of sarcopenia, which is a significant age-related condition affecting muscle mass and function, thus contributing to the understanding of aging processes.

Author of this paper? Send a correction.